This program contains embargoed material that will be presented at the ASBMR 2017 Annual Meeting in Denver, Colorado, USA, September 8-11, 2017.
If you are using this program on or before the day of presentation for a particular abstract, please note that the abstracts submitted to the ASBMR 2017 Annual Meeting are embargoed - that is, unavailable for public release in written, oral and electronic communications - until one hour after they have been presented.
The ASBMR is sensitive to issues of commercial confidentiality and relevant aspects of the U.S. Securities and Exchange Commission (SEC) Regulations. Therefore, all users of the ASBMR 2017 Annual Meeting Abstracts Online and Itinerary Builder must adhere to the Securities and Exchange Commission regulations and treat all information as confidential until the embargo has been lifted - one hour after the abstract has been presented. Users of this site may be viewed as "insiders" by the SEC due to their knowledge of information included in abstracts, particularly clinical trial abstracts. Acting on information included in these abstracts - prior to their public release after the embargo has been lifted - may subject individuals to criminal penalties.
By clicking on the link below ("I AGREE"), you will acknowledge your understanding of and agreement to uphold the ASBMR Embargo Policy, comply with the SEC Regulations, and to keep the content of all ASBMR abstracts confidential until the embargo has been lifted.
I understand the ASBMR Embargo Policy, which is that ASBMR abstracts are unavailable for public release in written, oral and electronic communications - until one hour after an abstract or abstracts has/have been presented.
Furthermore, I agree that under no circumstances will I share with others the information from abstracts or the abstracts themselves, nor will I make use of any "insider" information gained by previewing ASBMR abstracts. The abstracts are available for public release only after one hour following the time of their presentation.